Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms EMMY-Trial
- 03 Dec 2019 Planned End Date changed from 2 Apr 2020 to 2 Apr 2021.
- 03 Dec 2019 Planned primary completion date changed from 2 Nov 2019 to 2 Nov 2020.
- 31 Aug 2018 Biomarkers information updated